FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2290181978> ?p ?o ?g. }

• W2290181978 endingPage "53" @default.
• W2290181978 startingPage "3049" @default.
• W2290181978 abstract "Osteogenesis imperfecta (OI) is a rare bone disease and its effective treatment is relatively deficient. We tried to assess the effects of new bisphosphonate, ibandronate on children with OI.In this open-label, prospective, controlled study, 30 children with OI were enrolled. They received either infusions of ibandronate (2 mg) in every three months or oral calcitriol 0.25 µg daily for 24 months. All patients took 500 mg calcium plus 200 U vitamin D daily together. The endpoints were the change of annual new fracture rate (observed by case history and X ray films of spine), bone mineral density (BMD, measured by dual energy X-ray absortiometry), serum concentration of carboxy-telopeptide cross-links of type I collagen (CTX, bone resorption marker) and alkaline phosphatase (ALP, bone formation marker) during the follow-up.After the cyclic infusions of ibandronate, the annual new fracture rate was significantly decreased from 1.9 to 0.13 time, obviously lower than that of calcitriol group, which decreased from 1.8 to 1.0 time after the treatment (P < 0.001). The significant increase of BMD at the lumbar spine, femoral neck, trochanter, total hip was found in the group of ibandronate by 59.0%, 42.0%, 47.5% and 36.6% in time dependent manner (compared with the baseline, P < 0.001). The increase of BMD in ibandronate group was greater than that of calcitriol group (P < 0.001). The concentrations of ALP and CTX were obviously decreased in ibandronate group, and the reduction of CTX was more significant than that of ALP (P < 0.001). The tolerance of the children to ibandronate was quite well. Mild fever and muscle pain were found in 9 cases within 1 - 3 days after the first infusion of ibandronate, which could relieve after 1 - 2 days without special management.The benefits of cyclic infusions of ibandronate to children with OI are significant because ibandronate could significantly reduce annual bone fracture rate, increase lumbar and hip BMD, preserve vertebral morphometry of patients through inhibition of bone resorption." @default.
• W2290181978 created "2016-06-24" @default.
• W2290181978 creator A5009884211 @default.
• W2290181978 creator A5011545641 @default.
• W2290181978 creator A5015025675 @default.
• W2290181978 creator A5017223380 @default.
• W2290181978 creator A5047234646 @default.
• W2290181978 creator A5061766245 @default.
• W2290181978 creator A5065503728 @default.
• W2290181978 creator A5066505322 @default.
• W2290181978 creator A5067701828 @default.
• W2290181978 creator A5074196604 @default.
• W2290181978 creator A5090986135 @default.
• W2290181978 date "2011-10-01" @default.
• W2290181978 modified "2023-09-25" @default.
• W2290181978 title "Benefit of infusions with ibandronate treatment in children with osteogenesis imperfecta." @default.
• W2290181978 cites W144435506 @default.
• W2290181978 cites W1997446555 @default.
• W2290181978 cites W1997889859 @default.
• W2290181978 cites W2000075761 @default.
• W2290181978 cites W2003250911 @default.
• W2290181978 cites W2008205147 @default.
• W2290181978 cites W2021371637 @default.
• W2290181978 cites W2033277915 @default.
• W2290181978 cites W2050963690 @default.
• W2290181978 cites W2056536222 @default.
• W2290181978 cites W2057301391 @default.
• W2290181978 cites W2068830642 @default.
• W2290181978 cites W2071434898 @default.
• W2290181978 cites W2090991947 @default.
• W2290181978 cites W2108553370 @default.
• W2290181978 cites W2121073798 @default.
• W2290181978 cites W2150489401 @default.
• W2290181978 cites W2325596401 @default.
• W2290181978 cites W2012767560 @default.
• W2290181978 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22040553" @default.
• W2290181978 hasPublicationYear "2011" @default.
• W2290181978 type Work @default.
• W2290181978 sameAs 2290181978 @default.
• W2290181978 citedByCount "4" @default.
• W2290181978 countsByYear W22901819782014 @default.
• W2290181978 countsByYear W22901819782016 @default.
• W2290181978 countsByYear W22901819782018 @default.
• W2290181978 countsByYear W22901819782023 @default.
• W2290181978 crossrefType "journal-article" @default.
• W2290181978 hasAuthorship W2290181978A5009884211 @default.
• W2290181978 hasAuthorship W2290181978A5011545641 @default.
• W2290181978 hasAuthorship W2290181978A5015025675 @default.
• W2290181978 hasAuthorship W2290181978A5017223380 @default.
• W2290181978 hasAuthorship W2290181978A5047234646 @default.
• W2290181978 hasAuthorship W2290181978A5061766245 @default.
• W2290181978 hasAuthorship W2290181978A5065503728 @default.
• W2290181978 hasAuthorship W2290181978A5066505322 @default.
• W2290181978 hasAuthorship W2290181978A5067701828 @default.
• W2290181978 hasAuthorship W2290181978A5074196604 @default.
• W2290181978 hasAuthorship W2290181978A5090986135 @default.
• W2290181978 hasConcept C124490489 @default.
• W2290181978 hasConcept C125870589 @default.
• W2290181978 hasConcept C126322002 @default.
• W2290181978 hasConcept C126894567 @default.
• W2290181978 hasConcept C131075544 @default.
• W2290181978 hasConcept C134018914 @default.
• W2290181978 hasConcept C142724271 @default.
• W2290181978 hasConcept C160160445 @default.
• W2290181978 hasConcept C170033053 @default.
• W2290181978 hasConcept C181199279 @default.
• W2290181978 hasConcept C185592680 @default.
• W2290181978 hasConcept C2775854910 @default.
• W2290181978 hasConcept C2776079296 @default.
• W2290181978 hasConcept C2776541429 @default.
• W2290181978 hasConcept C2776886416 @default.
• W2290181978 hasConcept C2777251235 @default.
• W2290181978 hasConcept C2777668750 @default.
• W2290181978 hasConcept C2780644872 @default.
• W2290181978 hasConcept C55493867 @default.
• W2290181978 hasConcept C673006 @default.
• W2290181978 hasConcept C71924100 @default.
• W2290181978 hasConceptScore W2290181978C124490489 @default.
• W2290181978 hasConceptScore W2290181978C125870589 @default.
• W2290181978 hasConceptScore W2290181978C126322002 @default.
• W2290181978 hasConceptScore W2290181978C126894567 @default.
• W2290181978 hasConceptScore W2290181978C131075544 @default.
• W2290181978 hasConceptScore W2290181978C134018914 @default.
• W2290181978 hasConceptScore W2290181978C142724271 @default.
• W2290181978 hasConceptScore W2290181978C160160445 @default.
• W2290181978 hasConceptScore W2290181978C170033053 @default.
• W2290181978 hasConceptScore W2290181978C181199279 @default.
• W2290181978 hasConceptScore W2290181978C185592680 @default.
• W2290181978 hasConceptScore W2290181978C2775854910 @default.
• W2290181978 hasConceptScore W2290181978C2776079296 @default.
• W2290181978 hasConceptScore W2290181978C2776541429 @default.
• W2290181978 hasConceptScore W2290181978C2776886416 @default.
• W2290181978 hasConceptScore W2290181978C2777251235 @default.
• W2290181978 hasConceptScore W2290181978C2777668750 @default.
• W2290181978 hasConceptScore W2290181978C2780644872 @default.
• W2290181978 hasConceptScore W2290181978C55493867 @default.
• W2290181978 hasConceptScore W2290181978C673006 @default.
• W2290181978 hasConceptScore W2290181978C71924100 @default.

• next